Datopotamab Deruxtecan Biologics License Application Accepted by FDA for NSCLC Based on Phase III Trial Data
Datopotamab deruxtecan, the first TROP2-directed DXd antibody drug conjugate, is being evaluated for locally advanced or metastatic nonsquamous non-small cell lung cancer.
Examining the High Cost of the Drug Development Process
The drug development process, beginning with preclinical research up to when the product goes to market, requires time, risk, and high costs.
Use of AI in Treatment Strategies is Growing But Privacy Concerns Persist
Because artificial intelligence use in healthcare is powered by patient data, it is imperative to guard privacy by verifying that security measures are in place to protect against any data breaches.
Clinical Studies Show Efficacy of Test to Monitor Medication Treatment Response
Study highlights efficacy of effectively monitoring attention-deficit hyperactivity disorder treatment effects with Qbtest.
Report: Analyzing US Drug Shortages’ Impact on the Supply Chain
IQVIA report explores why these shortages are increasing, and how they can be mitigated.
DIA 2023: The Future of Biosimilars, Interchangeables
Panel explores challenges that could affect their development.
DIA 2023: The Impact of the IRA
Session offers a look into the Inflation Reduction Act’s impact on market conditions.
DIA 2023: Solving the Drug Pricing Problem
Session explores practicality of models for selling low-cost drugs.
DIA 2023: Digital Endpoints in Clinical Trials
Speakers dive into the importance of risk-based methods and central-monitoring solutions as they pertain to these trials.